Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Background and objective The causality assessment of drug-induced liver injury (DILI) remains a challenge and eagerly awaits the development of reliable hepatotoxicity biomarkers. None of the different available algorithms used for the causality assessment of DILI has been universally accepted as the gold standard. This study was conducted to examine the agreement among different causality assessment scales in reporting DILI.Methods The World Health Organization-Uppsala Monitoring Center (WHO-UMC), Naranjo, Roussel Uclaf Causality Assessment Method (RUCAM), Maria & Victorino (M & V) and Digestive Disease Week-Japan (DDW-J) assessment scales were used to compare the causalities in all the reported cases of DILI in our adverse drug reaction (ADR) monitoring centre from January 2014 to June 2017. The probability of the causality assessment was classified as 'definite', 'probable', 'possible' and 'unlikely'. The agreement obtained among the causality assessments was analysed using the weighted kappa (κ w) test.Results A total of 33 cases of DILI were included in our analyses. Anti-tubercular therapy (ATT) and methotrexate were the drugs that most commonly caused DILI. The overall agreement among the different scales was poor. The best agreement was found between RUCAM and DDW-J scales (κ w: 0.685).Conclusion There were discrepancies among the different causality scales in assessing DILI. This might be due to the different definitions of causality criteria and subjective variability during assessment. A personalised assessment scale incorporating the latest information on specific risk factors and evidence-based criteria for DILI is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, paracetamol accounted for a weighted mean of 55.7% (range 50.0-77.8%) of severe acute liver injury (ALI) and/or ALF [201-208] and 7.3% (range 1.2-29.2%) of drug-induced liver injury (DILI) [209-219] (see Figure 7).”
From Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease (2023) · cites this paper as [212]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit
Cohen, J. (1968) · Psychological Bulletin · doi:10.1037/h0026256 · Cited by 8,736
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Basic and Clinical Pharmacology
Katzung, B. G. (1982) · Andalas University Repository (Andalas University) · Cited by 1,914
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Fraunfelder, F. T. (1981) · American Journal of Ophthalmology · doi:10.1016/0002-9394(81)90318-4 · Cited by 1,331
Basic and clinical pharmacology
Traynor, J. R. (1988) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(88)80021-9 · Cited by 1,126
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Navarro, V. J., & Senior, J. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052270 · Cited by 811
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
RUCAM in Drug and Herb Induced Liver Injury: The Update
Danan, G., & Teschke, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010014 · Cited by 729
Benichou, C., Danan, G., & Flahault, A. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90102-7 · Cited by 491
Factors affecting the development of adverse drug reactions (Review article)
Alomar, M. J. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.02.003 · Cited by 484
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
Zapf, A., Castell, S., Morawietz, L., & Karch, A. (2016) · BMC Medical Research Methodology · doi:10.1186/s12874-016-0200-9 · Cited by 377
Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis
Maria, V. A., & Victorino, R. M. (1997) · Hepatology · doi:10.1002/hep.510260319 · Cited by 351
Hakkarainen, K. M., Hedna, K., Petzold, M., & Hägg, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033236 · Cited by 293
Causal or Casual?: The Role of Causality Assessment in Pharmacovigilance
Meyboom, R. H. B., Hekster, Y. A., Egberts, A. C. G., Gribnau, F. W. J., & Edwards, I. R. (1997) · Drug Safety · doi:10.2165/00002018-199717060-00004 · Cited by 240
The New Sentinel Network — Improving the Evidence of Medical-Product Safety
Platt, R., Wilson, M., Chan, K. A., Benner, J. S., Marchibroda, J., & McClellan, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0905338 · Cited by 228
Comparison of Two Clinical Scales for Causality Assessment in Hepatotoxicity
Lucena, M. I., Camargo, R., Andrade, R. J., Perez-Sanchez, C. J., & De La Cuesta, F. S. (2001) · Hepatology · doi:10.1053/jhep.2001.20645 · Cited by 212
Epidemiology of Idiosyncratic Drug-Induced Liver Injury
Bell, L., & Chalasani, N. (2009) · Seminars in Liver Disease · doi:10.1055/s-0029-1240002 · Cited by 197
Practical guidelines for diagnosis and early management of drug-induced liver injury
Tajiri, K., & Shimizu, Y. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6774 · Cited by 186
Causality assessment methods in drug induced liver injury: Strengths and weaknesses
García-Cortés, M., Stephens, C., Lucena, M. I., Fernández-Castañer, A., & Andrade, R. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.007 · Cited by 169
Rochon, J., Protiva, P., Seeff, L. B., Fontana, R. J., Liangpunsakul, S., Watkins, P. B., Davern, T., & McHutchison, J. G. (2008) · Hepatology · doi:10.1002/hep.22442 · Cited by 164
Data mining for signals in spontaneous reporting databases: proceed with caution
Stephenson, W. P., & Hauben, M. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1323 · Cited by 147
GARCÍA‐CORTÉS, M., LUCENA, M. I., PACHKORIA, K., BORRAZ, Y., HIDALGO, R., ANDRADE, R. J., & ON BEHALF OF THE SPANISH GROUP FOR THE STUDY OF DRUG‐INDUCED LIVER DISEASE (GRUPO DE ESTUDIO PARA LAS HEPATOPATÍAS ASOCIADAS A MEDICAMENTOS, G. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03655.x · Cited by 143
Adverse drug reaction and causality assessment scales
Zaki, S. (2011) · Lung India · doi:10.4103/0970-2113.80343 · Cited by 140
Causality Assessment of Drug-Induced Hepatotoxicity: Promises and Pitfalls
Shapiro, M. A., & Lewis, J. H. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.06.003 · Cited by 125
Accuracy of hepatic adverse drug reaction reporting in one English health region
Aithal, G. P., Rawlins, M. D., & Day, C. P. (1999) · BMJ · doi:10.1136/bmj.319.7224.1541 · Cited by 124
Coloma, P. M., Avillach, P., Salvo, F., Schuemie, M. J., Ferrajolo, C., Pariente, A., Fourrier‐Réglat, A., Molokhia, M., Patadia, V. K., van der Lei, J., et al. (2012) · Drug Safety · doi:10.1007/s40264-012-0002-x · Cited by 100
Assessing methods for causality assessment of suspected adverse drug reactions
Hutchinson, T. A., & Lane, D. A. (1989) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(89)90020-6 · Cited by 89
Ganesan, S., Selvarajan, S., Reddy, K. C., & Adithan, C. (2017) · Journal of Natural Science Biology and Medicine · doi:10.4103/0976-9668.210014 · Cited by 86
Self-citationMacedo, A. F., Marques, F. B., Ribeiro, C. F., & Teixeira, F. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1138 · Cited by 75
Pharmacovigilance programme of India
Kalaiselvan, V., Prakash, J., & Singh, G. (2012) · Archives of Pharmacy Practice · doi:10.4103/2045-080x.116605 · Cited by 73
Herbal hepatotoxicity: suspected cases assessed for alternative causes
Teschke, R., Schulze, J., Schwarzenboeck, A., Eickhoff, A., & Frenzel, C. (2013) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283603e89 · Cited by 73
Takikawa, H. (2003) · Hepatology Research · doi:10.1016/s1386-6346(03)00232-8 · Cited by 68
Biomarkers for the Diagnosis and Management of Drug-Induced Liver Injury
Watkins, P. (2009) · Seminars in Liver Disease · doi:10.1055/s-0029-1240008 · Cited by 65
Rathi, C., Pipaliya, N., Patel, R., Ingle, M., Phadke, A., & Sawant, P. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0009.8600 · Cited by 61
Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
Regev, A., Seeff, L. B., Merz, M., Ormarsdottir, S., Aithal, G. P., Gallivan, J., & Watkins, P. B. (2014) · Drug Safety · doi:10.1007/s40264-014-0185-4 · Cited by 51
ADRIC: Adverse Drug Reactions In Children – a programme of research using mixed methods
Smyth, R. L., Peak, M., Turner, M. A., Nunn, A. J., Williamson, P. R., Young, B., Arnott, J., Bellis, J. R., Bird, K. A., Bracken, L. E., et al. (2014) · Programme Grants for Applied Research · doi:10.3310/pgfar02030 · Cited by 49
Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate?
Teschke, R., & Wolff, A. (2010) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.09.006 · Cited by 44
WATANABE, M. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.08.005 · Cited by 44
The Food and Drug Administration algorithm. Special workshop—regulatory
Turner, W. M. (1984) · Drug Information Journal · doi:10.1177/009286158401800311 · Cited by 37
EU-ADR consortium, Ferrajolo, C., Coloma, P. M., Verhamme, K. M. C., Schuemie, M. J., de Bie, S., Gini, R., Herings, R., Mazzaglia, G., Picelli, G., et al. (2014) · Drug Safety · doi:10.1007/s40264-013-0132-9 · Cited by 30
Causal or casual? The role of causality assessment in pharmacovigilance
Meyboom, R. H. B., Hekster, Y. A., Egberts, T. C. G., Gribnau, F. W. J., & Edwards, I. R. (1997) · Radboud Repository (Radboud University) · Cited by 26
Palaniappan, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/13810.6704 · Cited by 25
García‐Cortés, M., Lucena, M. I., Andrade, R. J., Camargo, R., & Alcántara, R. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e007 · Cited by 23
Causality assessment: Which is best-expert opinion or RUCAM?
Lewis, J. H. (2014) · Clinical Liver Disease · doi:10.1002/cld.365 · Cited by 21
Antidepressant-Induced Acute Liver Injury: A Case–Control Study in an Italian Inpatient Population
on behalf of DILI-IT Study Group, Ferrajolo, C., Scavone, C., Donati, M., Bortolami, O., Stoppa, G., Motola, D., Vannacci, A., Mugelli, A., Leone, R., et al. (2017) · Drug Safety · doi:10.1007/s40264-017-0583-5 · Cited by 19
Miljkovic, M. M., Dobric, S., & Dragojevic‐Simic, V. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2081 · Cited by 17
(2013) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2013.d002x · Cited by 10
Stephens, C., López‐Nevot, M. Á., Lucena, M. I., Ruiz‐Cabello, F., Ulzurrun, E., Cabello, M. R., Fernández‐Santaella, M. C., Guarner, C., Soriano, G., Romero‐Gómez, M., et al. (2010) · Journal of Hepatology · doi:10.1016/s0168-8278(10)61138-5 · Cited by 5
Causality assessment of adverse drug reactions
Smyth, R. L., Peak, M., Turner, M. A., Nunn, A. J., Williamson, P. R., Young, B., Arnott, J., Bellis, J. R., Bird, K. A., Bracken, L. E., et al. (2014) · Cited by 2
Cited by
Chidiac, A. S., Buckley, N. A., Noghrehchi, F., & Cairns, R. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2223959 · Cited by 215
Pharmacovigilance – The next chapter
Moore, N. D., Berdaï, D., Blin, P., & Droz‐Perroteau, C. (2019) · Therapies · doi:10.1016/j.therap.2019.09.004 · Cited by 167
Roussel uclaf causality assessment method for drug-induced liver injury: Present and future
Danan, G., & Teschke, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00853 · Cited by 111
Teschke, R., & Danan, G. (2020) · Medicines · doi:10.3390/medicines7100062 · Cited by 77
“Das, 2018 [79] 24 Various drugs Cohort with limited feature description of few patients with DILI caused by drugs assessed for causality by RUCAM or other CAMs Dutta, 2020 [80] 1 Haloperidol Perfect presented feature details of DILI caused by this drug”
BackgroundTeschke, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00730 · Cited by 62
Metadata
- Authors
- Das, S., Behera, S. K., Xavier, A. S., Velupula, S., Dkhar, S. A., & Selvarajan, S.
- Affiliations
- Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
- Corresponding author
- Selvarajan, Sandhiya
- Venue
- Clinical Drug Investigation
- Published
- 2017-11-28
- Volume
- 38
- Issue
- 3
- Pages
- 211-218
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W2769098351
- Cited by
- 19
- References
- 56
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 1
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, causality assessment, interobserver agreement, RUCAM, WHO-UMC scale, adverse drug reaction reporting, liver injury biomarkers, tuberculosis treatment, methotrexate, drug safety
- MeSH terms
- Adolescent, Adult, Aged, Algorithms, Child, Female, Humans, India, Male, Middle Aged, Retrospective Studies, Risk Factors, World Health Organization, Biomarkers, Young Adult, Chemical and Drug Induced Liver Injury, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.